To explore the impact of glucose lowering treatment on prognosis in diabetic patients with myocardial infarction.
Introduction
The proportion of type 2 diabetes is as high as 20-30% among patients admitted for acute myocardial infarction. 1 -2 Due to better management the overall prognosis has improved following acute coronary events but patients with diabetes continue to have a considerably more dismal prognosis than their non-diabetic counterparts. 3 -4 Importantly, this increased risk is not only seen in older patients. In the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission (RIKS-HIA) the relative risk for 1 year mortality among diabetic patients were 1.66, 1.42, and 1.34 for the age groups ,65 years, 65-75 years, and .75 years compared with those without diabetes. 2 This excess, indeed an almost doubled mortality, has remained over the years indicating that benefits achieved in the non-diabetic patients with myocardial infarction have not to the same extent included those with diabetes. Factors of possible importance for the poor prognosis may relate to diabetes specific reasons, including diffuse coronary atherosclerosis, diabetic cardiomyopathy, autonomic neuropathy, metabolic factors, and an increased thrombogenicity. 5 Another factor may be a suboptimal use of evidence based management strategies although several treatment modalities, such as betablockade, and the use of statins are as beneficial in diabetic as in non-diabetic patients. 1, 3, 6 Uncertainties of the optimal glucose lowering treatment and deficiencies in reaching glucose treatment targets may also contribute to the unfavourable prognosis. It is firmly established that hyperglycemia is an important predictor for long-term outcome after acute coronary events. 7 -10 Thus, meticulous glucose control is important, but how this should be accomplished is not well established. In the first DIGAMI study, improved glucose control based on insulin caused a considerable decrease in longterm mortality. 8 These findings were, however, not verified in the second DIGAMI trial. The most likely explanation was the lack of difference in glucose control between the three study arms. 9 Indeed, a non-significant trend towards an increased morbidity in the form of non-fatal myocardial infarctions and stroke was observed among patients treated with insulin. As recently reviewed, oral glucose lowering with sulphonylureas have been questioned in patients with coronary artery disease (CAD) due to potentially harmful metabolic effects on ischaemic myocardium. 11 These concerns have, however, not been clinically verified. 12 In the United Kingdom Prospective Diabetes Study (UKPDS) metformin appeared to have survival benefits, but this was in a general diabetic population rather than in subjects with established CAD. 13 Furthermore, Nissen and Wolski 14 highlighted the need for long-term studies with glucose lowering agents, not only focusing on glycemic control but also on hard outcomes. Thus, it seems of great interest to further study the prognostic implications of glucose lowering drugs in patients with various CAD manifestations. This epidemiological report from DIGAMI 2 contains a detailed analysis of the impact of glucose lowering therapies on long-term prognosis in diabetic patients surviving the hospital phase of acute myocardial infarctions.
Methods
Patients DIGAMI 2, a prospective, randomized trial compared three different management strategies in patients with type 2 diabetes and suspect acute myocardial infarction. An extensive description of the study design has been presented elsewhere. 9 In brief, 1253 patients with established type 2 diabetes or an admission blood glucose .11.0 mmol/L, admitted to participating coronary care units, were eligible for inclusion according to the following criteria: suspect acute myocardial infarction due to symptoms (chest pain .15 min during the preceding 24 h) and/or recent ECG signs (new Q-waves and/or ST-segment deviations in 2 leads). They were randomized to one of three study arms receiving: (i) a 24 h insulin-glucose infusion followed by subcutaneous insulin-based long-term glucose control (n ¼ 474); (ii) the same initial treatment followed by standard glucose control (n ¼ 473); or (iii) glucose lowering treatment according to local practice (n ¼ 306). The objective was to compare total mortality and morbidity between these management strategies. There was no significant difference in the primary endpoint, total mortality. 9 Increasing plasma glucose was, however, an independent predictor of fatal outcome. The present patient material consists of the 1181 subjects who were discharged alive from the index hospitalization.
Treatment
Glucose-lowering treatment Group 1 and 2 were initially treated with a glucose -insulin infusion aiming at blood glucose between 7 -10 mmol/L as fast as possible and to be continued until stable normoglycemia and at least for 24 h. In group 1, the infusion was followed by multidose, subcutaneous insulin, short-and intermediate long-acting, targeting a fasting blood glucose between 5-7 mmol/L, and non-fasting ,10 mmol/L. Besides during the insulin-glucose infusion in group 2, there was no specified treatment goals in this group and group 3 with the choice of glucose lowering treatment left to the discretion of the responsible physician.
Concomitant treatment
The protocol stated that the use of concomitant treatment should be as uniform as possible and according to evidence-based international guidelines for acute myocardial infarction. 15, 16 Particular emphasis was put on prescribing aspirin, thrombolytic agents, beta-blockers, lipid-lowering drugs, Angiotensin-converting enzyme (ACE)-inhibitors, and revascularization procedures if appropriate and not contraindicated.
Laboratory investigations
Blood glucose was obtained at each follow-up visit to be reported as locally analysed whole blood glucose in mmol/L. Likewise blood lipids, serum creatinine, and electrolytes were analysed at the local laboratories. Glycated haemoglobin A1c (HbA1c) was analysed at a central core laboratory (Department of Laboratory Medicine, Malmö Hospital, Sweden) by high-performance liquid chromatography on capillary blood applied on filter paper with an upper normal limit of 5.3%. (Boehringer Mannheim Scandinavian AB, Bromma, Sweden) 17 
Follow-up
Out-patient visits were scheduled after 3, 6, 9, and 12 months and thereafter every sixth month. All patients were followed for a minimum of 6 months, whereas the maximum time of follow-up was 3 years. At each follow-up, a case record form was completed comprising information on fasting glucose, HbA1c, a detailed report on ongoing glucose lowering and other therapy and adverse events. Events including mortality, non-fatal infarctions, stroke, and coronary interventions were reported by means of special event forms.
Definitions
Myocardial infarction was diagnosed according to the joint ESC and ACC recommendations. 18 A re-infarction was defined as an event .72 h from the index infarction.
Stroke was defined as unequivocal signs of focal or global neurological deficit of sudden onset and vascular origin, lasting .24 h.
Deaths were verified with death certificates and autopsy reports when available. Sudden cardiovascular deaths were those that occurred within 24 h following onset of symptoms and without any other obvious reason for the fatal outcome. Deaths were labelled as cardiovascular or non-cardiovascular.
An independent committee composed of three experienced cardiologists, blinded for study group allocation, adjudicated all these events by means of case record forms, and relevant extracts from hospital records including laboratory values and electrocardiograms.
The impact of glucose lowering treatment Updated blood glucose was defined as the average value of all fasting glucose values. The first was recorded at the day of hospital discharge and subsequent values at each visit until that preceding an event or at the end of follow-up.
The use of drugs was updated at each visit until the last preceding an event or end of follow-up. This was done to ascertain that drugs added or excluded during the time of follow-up were taken into account when looking at the impact of therapy.
Local ethics review boards approved the protocol. Written informed consent was obtained from all patients prior to enrolment.
Statistics
The Cox proportional hazards model was the basis for the main analyses. In order to check the proportional hazards model, the proportionality was assessed by considering the interactions of the treatment indicators and time. In all adjusted multivariable models, predicting endpoints, the following covariates, recorded at the time for hospital admission, remained significant: age, smoking habits, previous myocardial infarction, previous congestive heart failure, creatinin at randomization, sex, percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass grafting (CABG) before randomization, and also during the hospitalization or blood glucose at randomization. The same set of variables was used for all endpoints. Thus, no model building procedures were used. Instead, covariates known to be predictive from the literature and the DIGAMI 2 study were applied. The first models used mainly baseline variables as covariates. No interaction terms was used due to limited power. Only insulin and blood glucose were used as time dependent variables. Blood glucose was preferred as a measure of glycemic control rather than HbA1c by several reasons as further outlined in the discussion. Initial variables for prediction of the use of insulin by a propensity score in a logistic regression were: current smoker, diabetes duration, myocardial infarction, heart failure, hypertension, PTCA, CABG, HbA1c, blood glucose, potassium, cholesterol, triglycerides, beta-blockers, aspirin, ACE-inhibitors, lipid lowering, diuretics, and time in hospital. In the final propensity score model, by using stepwise logistic regression, the following variables of those listed were selected: diabetes duration, heart failure, hypertension, blood glucose, and lipid lowering. The propensity score consisted of a linear combination of these variables. No interactions were allowed in this score. The c-statistics in the final model was 0.747. The c-statistics did not increase if all variables and interactions between variables were included. Due to missing values, a total of 1119 of 1181 patients (insulin n ¼ 656; non-insulin n ¼ 463) were included in the sensitivity analysis. The distribution of propensity score linear term for insulin patients was mean 0.87 (SD 1.18) compared with mean 20.04 (SD 0.78) for non-insulin patients. For all updated and adjusted endpoint analyses, the inclusion of the linear term of propensity score did not change the main results of this study.
Time in study was measured from the time of discharge from hospital. In the 'insulin at discharge' models, insulin status was characterized at the moment of discharge from hospital and kept as this value during follow-up. In the updated models insulin status varied and given an actual value each day (updated by day). Subsequently timedependent Cox proportional hazards model was used for updated variables. 19 Adjustments were done for prognostic variables at discharge and in addition updated blood glucose and updated insulin treatment (see Definitions) in order to account for variability in glucose control and the use insulin. For illustration purposes, we have chosen to present Kaplan-Meier curves estimated from Cox models and adjusted for variables at discharge using insulin/no insulin as strata. This information is given with the time dependent adjusted Hazard ratio (HR) as a complement. Twotailed statistical tests were used at a 5% significance level. SAS version 8:02 was used for all statistical analyses.
Results

Characteristics at baseline
The total DIGAMI 2 cohort consisted of 1253 patients with type 2 diabetes of whom 1181 (94%), the present population, were discharged alive. The clinical characteristics, biochemical data, and treatment at hospital discharge are presented in Table 1 dividing the patients by insulin treatment. The median study duration was 2.1 (inter-quartile range 1.03 -3.00) years, and no patient was lost to follow-up. The median time of follow-up was 2.1 years (mean 2.0 + 0.9) for patients on insulin and 2.5 years (mean 2.1 + 0.9) for the remaining patients. Newly detected diabetes, defined as of duration ,1 year, was seen in 251 of the 1181 patients (21%). At hospital discharge, 1011 patients (86%) fulfilled the diagnosis of myocardial infarction whereof 47% had Q-wave and 53% non-Q-wave infarctions. Of the remaining hospital survivors, 111 had CAD (unstable angina pectoris n ¼ 58) and 59 miscellaneous diagnoses.
Treatment
The distribution of patients on various oral glucose lowering drugs and on insulin is presented in Table 2 . At the time for discharge, 436 patients were treated with oral glucose lowering agents, 268 (61%) with sulphonylureas, 200 (46%) metformin, and 9 (2%) acarbos. At discharge, 690 patients (58%) were on insulin while 176 (15%) did not receive any pharmacological glucose lowering treatment. A total of 173 (15%) patients were on a combination of various glucose lowering agents. The proportion of patients on insulin remained stable over the time of follow-up (after 12 months ¼ 58%; 24 months ¼ 60%; 36 months ¼ 63%).
Mortality and morbidity
During follow-up, 206 of the 1181 patients died while 162 and 54 had non-fatal myocardial infarction or stroke respectively. The impact of glucose lowering drugs on cardiovascular events was analysed in three steps. The first compared all different glucose lowering therapies (insulin, oral, or no pharmacological) with each other as regards cardiovascular events. Following adjustment none of the oral glucose-lowering treatments were associated with improved survival during the study period ( Figure 1) . However, the likelihood to develop a non-fatal myocardial reinfarction or stroke was significantly lower in patients on metformin (P ¼ 0.0269) while sulphonylureas did not relate to morbidity.
The effects of insulin on mortality and cardiovascular events are presented in Table 3 and Figure 2A and B. Insulin was not associated with all cause (adjusted HR 1.19, 95% CI 0.88-1.60; P ¼ 0.2575) or cardiovascular mortality (adjusted HR 1.14, 95% CI 0.82-1.60; P ¼ 0.4284) but with an increased proportion of non-fatal reinfarction or stroke (adjusted HR 1.71, 95% CI 1.25-2.35; P ¼ 0.0008).
The statistical models were also tested for consistency by adding propensity score with hypertension, ACE-inhibitors, lipid lowering drugs, diuretics, diabetes duration and time at hospital as covariates. The results were not influenced by any of the added corrections.
Thirty-two per cent of the patients (n ¼ 375) discharged alive were already on insulin at hospital admission. To look at the effect of newly instituted insulin a second analysis was made including all patients (n ¼ 317), who were prescribed new insulin during the initial hospitalization (n ¼ 245 from study group1 and n ¼ 72 from study groups 2 and 3). They were compared with all patients (n ¼ 489), who never had been on insulin and who were discharged without such therapy. Updated information on insulin was used in the analysis adjusted for baseline variables and updated glucose. The observation that insulin related to an increased risk for non-fatal myocardial infarction or stroke compared with non-insulin based treatment remained (adjusted HR 1.95, 95% CI 1.35-2.82; P ¼ 0.0004; Table 3 and Figure 3A and B) in this subgroup. Newly instituted insulin did not relate to all cause (adjusted HR 1.09, 95% CI 0.74-1.61; P ¼ 0.6631) or cardiovascular (adjusted HR 1.11, 95% CI 0.72-1.72; P ¼ 0.6237) mortality.
Finally, a third analysis compared all patients that were randomized to and discharged with new insulin according to the study protocol (study group 1; n ¼ 245) with patients (n ¼ 422) in groups 2 and 3 without insulin at admission and discharge i.e. without chronic insulin therapy. Clinical and biochemical characteristics for these two groups are presented in Table 4 . As can be seen there were few differences between the groups compared with what was seen when looking at all patients with and without insulin therapy ( Table 1) . As outlined in Table 3 , the significantly increased risk for myocardial infarction or stroke remained even in this cohort (HR 2.07, 95% CI 1.37-3.14; P ¼ 0.0006). When the propensity score was added into the models of Table 3 , the results did not change.
Discussion
The important message from this epidemiological analysis of the DIGAMI 2 trial is that the agent used for long-term glucose control may play a considerable role for the development of future non-fatal cardiovascular events. Chronic insulin was Updated Insulin. c Baseline adjustment: age, smoking habits, previous MI, previous chronic congestive heart failure creatinine at randomization, sex, percutaneous transluminal coronary angioplasty before randomization or during the hospitalization, CABG before randomization or during the hospitalization, blood glucose at randomization. The impact of glucose lowering treatment associated with an increased number while metformin was beneficial and sulphonylureas neutral in this respect.
The present observations are based on a prospectively composed and regularly followed group of diabetic patients. The study design allowed successive updating of fasting glucose and treatment modalities. The total number of patients (n ¼ 1181) and events (n ¼ 422) was large, and all events were adjudicated by an independent committee. Updated blood glucose was preferred as a measure of glycemic control partly because a total of 253 HbA1c analyses were reported as missing while the information on blood glucose was complete. Glucose was an independent and strong predictor of mortality, indeed stronger than HbA1c in the DIGAMI 2 trial. 9 Furthermore, the half-life of HbA1c of 3 months makes this variable a more blunt expression of glucose control than fasting glucose in a study with limited follow-up. Moreover, updated glucose should reflect the glycemic control more accurately than the use of occasional glucose levels e.g. at the time for hospital discharge or closest to an event. Previous reports on diabetic post-infarction patients are often based on subgroup analysis of clinical trials or registry studies, which by necessity introduce uncertainties in the definition of the diabetic state and glucose lowering treatment as well as long-term glucose control. 12,20 -23 The vast majority of patients on oral glucose lowering treatment in DIGAMI 2 got sulphonylureas or metformin. Sulphonylureas did not relate to mortality and morbidity. Since the original report by the University Group Diabetes Program, 24 the use of sulphonylureas has been questioned and claimed to increase cardiovascular mortality, especially in patients at a high cardiovascular risk. 11, 12, 20 The proposed explanation is a combination of harmful effects on vascular tone and interference with ischaemic preconditioning. 25 Riveline et al. 26 made a systematic literature review of experimental, epidemiological and clinical studies. The authors concluded that the cardiac effects of sulphonylureas differ between the first and second generation. The only presently available, prospective, clinical study, UKPDS, 27 did not report on any deleterious effects of glibenclamide compared with chlorpropamide and insulin. The present findings support the view that sulphonylureas may be used without harm. Glucose lowering by means of metformin did not influence mortality but was related to a lower proportion of non-fatal cardiovascular events. The latter finding is in agreement with UKPDS 13 but in this study metformin did also have a mortality lowering effect. The discrepancy is most likely explained by differences in the studied populations and time of follow-up. UKPDS comprised patients with newly detected diabetes without previous cardiovascular disease, whereas DIGAMI 2 recruited diabetic patients with acute myocardial infarction reasonably at a substantially higher risk. It is not unlikely that the lower incidence of non-fatal cardiovascular events in metformin treated patients in DIGAMI 2 may reduce mortality during extended follow-up. The most surprising finding was the increase in non-fatal cardiovascular events seen with the use of insulin compared with oral glucose lowering agents or life-style measures only. It should be underlined that this observation was made following adjustment for updated glucose i.e. cannot be explained by a less efficient glycemic control by insulin. It is unlikely that the findings are explained by insulin serving as a marker for a more serious clinical condition since the untoward effect remained following adjustment for a number of variables related to the condition and treatment of the patients including a propensity score. Furthermore the three steps of analyses were completely consistent. A potentially harmful effect of insulin on cardiovascular mortality and morbidity has been discussed based on registry studies or subgroup analysis of a clinical trial. Nichols et al. 28 and Smooke et al. 22 reported on an increased incidence of heart failure and an enhanced mortality in heart failure among diabetic patients on insulin compared with patients on non-insulin based therapy, respectively. The SYMPH-ONY investigators 21 noted that insulin providing (insulin or sulphonylureas) compared with insulin sensitizing (biguanides and/or thiazolidinedione) post-myocardial infarction treatment in diabetic patients related to a significantly higher event rate. Johnsen et al.
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performed a registry based review of glucose lowering drugs given to patients hospitalized for a first myocardial infarction who were compared with population based controls. Patients prescribed insulin had a higher rate of myocardial infarction than those on oral glucose lowering drugs. These findings have, however, not been proven in prospective, well-defined patient populations. This makes the present observation that the composite endpoint of mortality and non-fatal myocardial infarction, and stroke was significantly more frequent among patients on chronic insulin of particular interest. This increase was largely driven by a higher number of non-fatal cardiovascular events although a non-significant trend towards a higher mortality was observed. It may be speculated that the higher number of non-fatal cardiovascular events would enhance the mortality difference by time. The separate analysis on patients with newly instituted insulin did not change the pattern. Thus, the dismal impact cannot be explained by longer periods on insulin. The final analysis, including only patients randomly allocated to insulin, was made to as far as possible exclude a prescription bias in the direction that insulin more often was administered to patients with advanced disease. The outcome confirmed and further strengthened the observation made in the total patient cohort. The present finding contrasts the results of DIGAMI 1 in which insulin based glucose control improved long-term mortality. 8 An important difference between the two DIGAMI trials is that the first succeeded in getting a significantly better glucose control in the insulin-based treatment arm, whereas glucose control was similar with oral glucose lowering agents and insulin in the latter. This fits with observations made by Van den Berghe et al. 29, 30 that meticulous metabolic control, rather than insulin per se, has a positive effect on mortality and morbidity at least in a short-term perspective. The interpretation would be that, if insulin is used for glucose control, it is important that the treatment target is normoglycemia in order to balance the favourable impact of glucose control against a potentially harmful effect of insulin in itself.
Limitations
The present epidemiological analysis does only permit speculations on the reasons for the harmful effects of insulin. Deleterious effects have mostly been related to endogenous hyperinsulinaemia although some reports addressed exogenous insulin. Negative effects on endothelial function, sympathetic nervous system activation, smooth muscle cell hypertrophy, impaired fibrinolysis, and induction of platelet dysfunction have been discussed as potential pathophysiological factors. 31 -37 Moreover, a pro-atherogenic effect of insulin may be mediated by growth factor like activity. 38 Although based on a well-defined patient material, it should be acknowledged that data presented are based on an epidemiological analysis. Despite adjustments, including the use of a propensity score, there still is a possibility of confounding by indication due to unobserved covariates. Bias may therefore remain in the treatment estimation. It is, however, unlikely that the main finding, an untoward impact of insulin, is an expression of such confounding. Newly instituted insulin was mainly prescribed according to the randomization of patients to study group 1, and the observation of a trend towards increased mortality and a higher number of non-fatal cardiovascular events remained in the separate analysis of this group. Another limitation is the relatively short period of follow-up. Finally, the possibility for competing risk has to be discussed. Since there were no significant mortality differences between the various glucose lowering treatments the exposure for non-fatal events should not have been much different between treatment with metformin, sulphonylureas, and insulin thereby reducing competing risk as an explanation to the present results.
Conclusions
Controlling for confounders including updated blood glucose, there was no significant difference in mortality between sulphonylureas, metformin, and insulin. In this post hoc analysis, the risk of non-fatal myocardial infarction or stroke was higher in patients on insulin treatment while metformin seemed to be protective. Whether this difference will translate into increased mortality can only be answered by more extensive periods of follow-up. The present observations make it important to further study the impact of insulin in a randomized study design and to search for other pharmacological glucose lowering agents. It also underlines the safety of the oral glucose lowering agents, sulphonylureas and metformin, in postmyocardial infarction patients with diabetes mellitus.
